ClinicalTrials.gg
CompletedNCT03322631Updated Mar 23, 2023Results posted

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

A Phase 1 interventional study of Tirzepatide and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
37th of 43
48 · median 160
Started
2017
with 2 others
Phase 1
8 of 43
none open now
Registered
4th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 1, and was the 4th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purposes of this study are to determine:

  • The safety of tirzepatide and any side effects that might be associated with it.
  • How much tirzepatide gets into the bloodstream and how long it takes the body to remove it.
  • How tirzepatide affects the levels of blood sugar.

This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin or dipeptidyl peptidase [DPP]-IV inhibitors)
  • Have a of 20.0 to 35.0 kilograms per square meter, inclusive

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to tirzepatide, glucagon-like peptide (GLP)-1 analogs, or related compounds
  • Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • Have an abnormality in the 12-lead at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history or presence of pancreatitis or gastrointestinal (GI) disorder or any GI disease which impacts gastric emptying or could be aggravated by GLP-1 analogs or DPP-IV inhibitors
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received placebo administered into the SC tissue of the abdominal wall.

    Drug: Placebo

Interventions

  • Administered SC.

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Safety was assessed from time of consent through end of study (up to 85 days). Data presented are the number of participants who experienced 1 or more SAEs considered by the investigator to be related to study drug. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.

    Time frame: Baseline through Day 85

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Tirzepatide

    Pharmacokinetics (PK): Maximum observed drug concentration (Cmax) of Tirzepatide in plasma.

    Time frame: Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide

    Area under the concentration versus time curve from time zero to tau (τ) of Tirzepatide (AUC\[0- τ\]), where tau is dosing interval of (0-168 hours).

    Time frame: Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration

  3. Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose

    Change from baseline to 8 weeks in Fasting Plasma Glucose was measured to investigate the PD effect of Tirzepatide after multiple SC doses administered to Japanese patients with T2DM

    Time frame: Baseline, Week 8

07

Results

Posted Mar 23, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
Started9121611
Received at least 1 dose of study drug9121611
Completed9111511
Not completed0110
Withdrew: Withdrawal by subject0100
Withdrew: Adverse event0010

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Safety was assessed from time of consent through end of study (up to 85 days). Data presented are the number of participants who experienced 1 or more SAEs considered by the investigator to be related to study drug. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.

Time frame:
Baseline through Day 85
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Tirzepatide

Pharmacokinetics (PK): Maximum observed drug concentration (Cmax) of Tirzepatide in plasma.

Time frame:
Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Tirzepatide
nanograms per milliliter (ng/mL)2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
Day 1215 ± 18442 ± 23364 ± 20
Day 501520 ± 152270 ± 17838 ± 22
SecondaryPK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide

Area under the concentration versus time curve from time zero to tau (τ) of Tirzepatide (AUC\[0- τ\]), where tau is dosing interval of (0-168 hours).

Time frame:
Predose, 8, 24, 48, 72 and 168 hours post dose for Day 1 administration, and Predose, 8, 24, 48, and 168 hours post dose for Day 50 administration
Reported as:
Geometric mean · nanograms * hours per mL (ng*hr/mL)
PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide
nanograms * hours per mL (ng*hr/mL)2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
Day 126100 ± 2754400 ± 1648800 ± 16
Day 50192000 ± 16285000 ± 15104000 ± 19
SecondaryPharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose

Change from baseline to 8 weeks in Fasting Plasma Glucose was measured to investigate the PD effect of Tirzepatide after multiple SC doses administered to Japanese patients with T2DM

Time frame:
Baseline, Week 8
Reported as:
Mean · milligram per deciliter (mg/dL)
Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose
milligram per deciliter (mg/dL)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose-4.0 ± 23.7-77.5 ± 24.2-72.6 ± 30.9-51.7 ± 28.9

Adverse events

Collected over Up To 85 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/9 (0%)0/9 (0%)4/9 (44.4%)
2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)0/12 (0%)0/12 (0%)11/12 (91.7%)
5 mg/10 mg/15 mg Tirzepatide (Cohort 2)0/16 (0%)0/16 (0%)15/16 (93.8%)
5 mg Tirzepatide (Cohort 3)0/11 (0%)0/11 (0%)6/11 (54.5%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlacebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)
ConstipationGastrointestinal disorders1/98/128/160/11
Decreased appetiteMetabolism and nutrition disorders0/96/1210/165/11
DiarrhoeaGastrointestinal disorders0/93/125/160/11
Abdominal distensionGastrointestinal disorders1/91/120/163/11
Abdominal discomfortGastrointestinal disorders0/92/124/160/11
DyspepsiaGastrointestinal disorders0/93/120/160/11
HeadacheNervous system disorders0/93/121/160/11
Blood triglycerides increasedInvestigations2/90/121/160/11
NauseaGastrointestinal disorders0/90/122/161/11
VomitingGastrointestinal disorders0/91/122/161/11

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
Mean57.4 ± 11.656.9 ± 9.557.7 ± 8.057.5 ± 7.957.4 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
Female00101
Male912151147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
Hispanic or Latino00000
Not Hispanic or Latino912161148
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
American Indian or Alaska Native00000
Asian912161148
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
Japan912161148
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Placebo2.5 mg/5 mg/10 mg Tirzepatide (Cohort 1)5 mg/10 mg/15 mg Tirzepatide (Cohort 2)5 mg Tirzepatide (Cohort 3)Total
Mean22.58 ± 2.0925.49 ± 2.7526.10 ± 3.1126.68 ± 3.2925.42 ± 3.16
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Hachioji, Tokyo 192-0071, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Shinjuku-Ku, Tokyo 169-0073, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2018, 6 months.

Results were first posted in Mar 2023, 4 years 9 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2017
First posted
Oct 26, 2017
StartActual
Nov 15, 2017
Primary completionActual
May 29, 2018
CompletionActual
Nov 28, 2018
Results first posted
Mar 23, 2023
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03322631
Responsible party
Sponsor
First posted
Oct 26, 2017
Start date
Nov 15, 2017
Primary completion
May 29, 2018
Completion
Nov 28, 2018
Results posted
Mar 23, 2023
Last update
Mar 23, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion